Page last updated: 2024-12-06
p-chloro-o-toluidine hydrochloride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
p-chloro-o-toluidine hydrochloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 18487 |
| CHEMBL ID | 3182298 |
| SCHEMBL ID | 131186 |
| MeSH ID | M0555395 |
Synonyms (86)
| Synonym |
|---|
| azogene fast red tr |
| 4-chloro-o-toluidine.hcl |
| c.i. 37085 |
| nsc7629 |
| devol red k |
| devol red ta salt |
| fast red salt tra |
| fast red salt tr |
| devol red tr |
| nsc-7629 |
| kromon green b |
| 4-chloro-2-methylaniline hydrochloride |
| fast red 5ct salt |
| azoic diazo component 11 base |
| brentamine fast red tr salt |
| azanil red salt trd |
| 4-chloro-2-methylbenzenamine hydrochloride |
| 3165-93-3 |
| c.i. azoic diazo component 11 |
| 4-chloro-o-toluidine hydrochloride |
| hindasol red tr salt |
| fast red tr salt |
| p-chloro-o-toluidine hydrochloride |
| red trs salt |
| neutrosel red trva |
| 4-chloro-o-toluidine (nh2=1) hydrochloride |
| red salt ciba ix |
| red salt irga ix |
| amarthol fast red tr salt |
| 4-chloro-6-methylaniline hydrochloride |
| 5-chloro-2-aminotoluene hydrochloride |
| 2-amino-5-chlorotoluene hydrochloride |
| azoene fast red tr salt |
| nci-c02368 |
| natasol fast red tr salt |
| diazo fast red tr |
| 4-chloro-o-toluidine (nh2=1) |
| daito red salt tr |
| fast red salt trn |
| 2-methyl-4-chloroaniline hydrochloride |
| wln: zr dg b1 &gh |
| chlorhydrate de 4-chloroorthotoluidine |
| 4-chloro-2-toluidine hydrochloride |
| ofna-perl salt rra |
| sanyo fast red salt tr |
| ci azoic diazo component 11 |
| nsc 7629 |
| o-toluidine, 4-chloro-, hydrochloride |
| un1579 |
| chlorhydrate de 4-chloroorthotoluidine [french] |
| amarthol fast red tr |
| rcra waste number u049 |
| asymmetric meta-chloro-ortho-toluidine hydrochloride |
| clorhidrato de 4-cloro-o-toluidine |
| rcra waste no. u049 |
| ccris 153 |
| benzenamine, 4-chloro-2-methyl-, hydrochloride |
| hsdb 6191 |
| chlorhydrate de chloro-4 o-toluidine |
| einecs 221-627-8 |
| 4-chloro-o-toluidinium chloride |
| 4-chloro-o-toluidine hydrochloride [un1579] [poison] |
| unii-1y82dn556p |
| 1y82dn556p , |
| benzenamine, 4-chloro-2-methyl-, hydrochloride (1:1) |
| 4-chloro-o-toluidine hcl |
| cas-3165-93-3 |
| NCGC00256591-01 |
| tox21_302920 |
| dtxcid20288 |
| dtxsid0020288 , |
| NCGC00258835-01 |
| tox21_201283 |
| FT-0618236 |
| 4-chloro-o-toluidine hydrochloride [hsdb] |
| SCHEMBL131186 |
| 2 -amino-5 -chlorotoluene hydrochloride |
| VKYZDCTWJGBFDW-UHFFFAOYSA-N |
| AKOS016846210 |
| CHEMBL3182298 |
| 4-chloro-2-methylaniline hydrochloride, aldrichcpr |
| J-018507 |
| Q27253163 |
| 4-chloro-2-methylaniline;hydrochloride |
| D89231 |
| 4-chloro-o-toluidinehydrochloride |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " 4-CloT was administered orally over 28 consecutive days (days 1-28), followed by a 28-day treatment-free (days 29-56), and a second dosing phase of 3 days (days 57-59)." | ( DNA Damage Response of 4-Chloro-Ortho-Toluidine in Various Rat Tissues. Christen, F; Funk, J; Guérard, M; Marchand, C; Winter, M; Zeller, A, 2018) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (8)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 40.8562 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 53.6069 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 76.7209 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 22.9752 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 4.3647 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 21.8751 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 29.7011 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 60.4918 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.32
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.32) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||